Saniona Publishes Its Interim Report For The Second Quarter 2017
PRESS RELEASE
23 August 2017
Financial highlights
H1 2017 (H1 2016)
· Net revenues were SEK 11.9 M (18.9 M)
· EBIT was SEK -25.4 M (-14.6 M)
· Earnings per share were SEK -1.00 (-0.61)
· Diluted earnings per share were SEK -1.00 (-0.61)
Q2 2017 (Q2 2016)
· Net revenues were SEK 4.3 M (3.0 M)
· EBIT was SEK -17.9 M (-13.5 M)
· Earnings per share were SEK -0.69 (-0.49)
· Diluted earnings per share were SEK -0.69 (-0.49)
Business highlights in Q2 2017
· Saniona initiates Phase 2a study for Tesomet in Prader-Willi syndrome
· Saniona's partner, Medix, obtains regulatory approval to initiate a Phase 3 study for tesofensine in obesity
· Saniona obtains research milestone from The Michael J. Fox Foundation for Parkinson's Research
· Saniona participates in formation of Scandion Oncology and spins out clinical program and related ion channel platform
· Saniona completes private placement for SEK 35 million
· Saniona is listed on Nasdaq Stockholm Small Cap
Significant events after the reporting period
· Saniona buys out future payment obligation to NeuroSearch
· Saniona's partner, Luc Therapeutics, nominates clinical candidate and initiates preclinical development in joint Ataxia program
· Saniona's partner, Medix, initiates Phase 3 study for tesofensine in obesity
Comments from the CEO
"This week Saniona became a Phase 3 company. After only five years of operation, we have one program in Phase 3, two in Phase 2, one in preclinical development and five active research programs. We are now listed on the main market and have more than 5,000 shareholders. I look forward to the future with excitement," says Jørgen Drejer, CEO of Saniona.
Read the complete Interim Report attached below.
For more information, please contact
Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: tf@saniona.com
The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on 23 August 2017.
About Saniona
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at preclinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, Proximagen Ltd., Productos Medix, S.A de S.V and Luc Therapeutics Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq Stockholm Small Cap and has about 5,100 shareholders. The company's share is traded under the ticker SANION. Read more at www.saniona.com.
Attachments:http://www.globenewswire.com/NewsRoom/AttachmentNg/92cd4791-964f-42ac-8597-d298294c42f9